Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...
Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. | The leaders of Chugai ...
Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...
Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...
The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback